Natural products are essential in drug development, with increasing interest in lichen-derived compounds for their therapeutic potential. This study investigates the bioactivity of the methanolic extract of Hypotrachyna cirrhata through in vitro and in silico approaches. The ethyl acetate fraction demonstrated the highest DPPH radical scavenging activity, with an IC50 of 10.37 ± 0.62 μg/mL, while the methanolic extract exhibited an IC50 of 72.30 ± 0.55 μg/mL. For α-glucosidase inhibition, the ethyl acetate fraction and crude extract showed IC50 values of 1.17 ± 0.50 μg/mL and 5.00 ± 0.45 μg/mL, respectively. Antibacterial assays revealed zones of inhibition of 12 and 11 mm against Staphylococcus aureus at 25 mg/mL, with the strain showing sensitivity to the methanolic extract (MIC of 20.0 × 10−4 mg/mL). LC-MS analysis identified eight metabolites in the ethyl acetate extract, salazinic acid (1), roccellaric acid (2), constictic acid (3), protolichesterinic acid (4), mannitol (5), penta hydroxyicosatrienoicacid (6), methyl pentahydroxyoxoheptacosanoate (7), and one unknown compound. Five major compounds (1-5) were selected for computational analysis and highlighted that salazinic acid as a potential lead compound, displaying a non-competitive binding with α-glucosidase and a binding affinity of −9.9 kcal/mol. These findings suggest salazinic acid's promise as an α-glucosidase inhibitor.
Read full abstract